- Home
- ATRA vs TVRD Comparison
ATRA vs TVRD Comparison
Compare ATRA & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | TVRD |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 34.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATRA | TVRD |
|---|---|---|
| Price | $10.34 | $3.41 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.00 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 3.2M | 40.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,772,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.92 | $2.75 |
| 52 Week High | $19.15 | $43.65 |
Technical Indicators
Market Signals| Indicator | ATRA | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 67.90 | 40.99 |
| Support Level | $4.35 | $2.83 |
| Resistance Level | $12.91 | $4.32 |
| Average True Range (ATR) | 1.45 | 0.31 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 59.47 | 2.78 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.